
    
      The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the MERS-CoV
      spike glycoprotein (S). A total of 24 participants will receive the following vaccine regime:

      12 participants will receive 10^7 plaque-forming units (PFU) of MVA-MERS-S on days 0 and 28.

      12 participants will receive 10^8 PFU of MVA-MERS-S on days 0 and 28.

      Safety and immunogenicity data will be collected throughout the study, which concludes at day
      180.

      Update March 2019: A subgroup of participants from both dose cohorts will receive a late
      booster immunization of 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime
      immunization.
    
  